Non Injectable Insulin Market
Non-Injectable Insulin Market Forecasts to 2030 - Global Analysis By Product (Oral, Transdermal, Nasal, Sublingual and Other Products), Dosage, Distribution Channel and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $1.4 BN |
|
Projected Year Value (2030) |
US $4.0 BN |
|
CAGR (2023 - 2030) |
15.2% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Non-Injectable Insulin Market is accounted for $1.4 billion in 2023 and is expected to reach $4.0 billion by 2030 growing at a CAGR of 15.2% during the forecast period. Non-injectable insulin refers to forms of insulin that do not require injection through a needle into the skin but instead can be administered through alternative methods. These techniques can be applied topically as patches or through inhalation, oral medication, or nasal sprays. With the introduction of non-injectable insulin, people who need insulin therapy will have more convenient options, which could lead to better treatment adherence and an overall improvement in quality of life.
According to Biocon, it terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus.
Market Dynamics:
Driver:
Technological developments in medicine delivery
The continuous progress in medication delivery technology is a major driver of the market's growth. The field of diabetes management is changing as a result of these innovative technical advancements, which make non-injectable insulin substitutes more dependable, efficient, and appealing to patients and medical professionals alike. Furthermore, these developments have improved insulin dose accuracy and consistency, increasing the overall effectiveness of non-injectable insulin devices.
Restraint:
Side effects
Like any medication, non-injectable insulin can have side effects. Inhaled insulin might cause coughing or throat irritation. Oral insulin might interact with digestive enzymes or cause gastrointestinal issues. The reluctance of patients to embrace non-injectable insulin techniques presents a significant obstacle to the market's growth. Even with the obvious benefits and ease of use of non-injectable insulin alternatives, some people are reluctant to abandon the comfortable and well-recognized method of insulin injections.
Opportunity:
Rising diabetes prevalence
Alternative insulin administration systems are becoming more and more popular as diabetes becomes more commonplace worldwide. Non-injectable alternatives present a compelling substitute for diabetes individuals who may be uncomfortable with or struggle with injections. Increased adoption and market expansion are also facilitated by initiatives to inform patients, medical professionals, and the general public about the availability and advantages of non-injectable insulin solutions.
Threat:
High cost
If approved, non-injectable insulin may cost more than conventional injectable insulin. Expenses may rise as a result of R&D and technological advancements in delivery systems. Regulators have encountered difficulties with the development and approval of non-injectable insulin, though. Regulatory scrutiny and lengthy clinical trials are frequently necessary to ensure safety and efficacy for general use. The market's expansion is being hindered by these factors.
Covid-19 Impact:
The market for non-injectable insulin has been affected by the COVID-19 pandemic in a variety of ways. The initial interruption of the supply chain and limited accessibility to healthcare facilities notwithstanding, there was an increasing demand for creative solutions to treat diabetes. There was an increase in demand for non-injectable insulin options as patients looked for alternatives to lessen their hospital visits. In addition, the epidemic hastened the use of telemedicine, facilitating patient access to and discussion of these choices with medical professionals.
The sprays segment is expected to be the largest during the forecast period
The sprays segment is expected to be the largest during the forecast period due to its convenience and patient-friendly attributes. Patients looking for simpler and less unpleasant ways to manage their diabetes may find inhalable insulin sprays appealing as a less intrusive substitute for injections. Furthermore, these sprays guarantee accurate and efficient dosage due to notable developments in drug delivery technology.
The hospital pharmacies segment is expected to have the highest CAGR during the forecast period
The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Healthcare facilities play a pivotal role in the management and treatment of diabetes, rendering them notable hubs for the delivery of insulin products that are not injectable. Trust in non-injectable insulin alternatives is fostered by the clinical context of hospitals. A broad patient population can benefit from the promotion and provision of non-injectable insulin solutions by hospital pharmacy due to the confluence of these variables.
Region with largest share:
North America is projected to hold the largest market share during the forecast period. High diabetes prevalence, a robust healthcare infrastructure, and a strong emphasis on research and innovation in the region contribute to its prominence. Notable are the patient's awareness and readiness to switch to non-injectable insulin substitutes. The region's significant market share is cemented by the high need for accessible and patient-focused diabetes treatment solutions.
Region with highest CAGR:
Asia Pacific is projected to hold the highest CAGR over the forecast period. The region's high diabetes prevalence, rapid urbanization, and expanding healthcare infrastructure have contributed to increased demand for innovative diabetes management solutions. Initiatives from the government and partnerships with pharmaceutical firms have further encouraged market expansion. Because of this, it is positioned as a significant player in the market thanks to its large and diverse patient population and encouraging healthcare programs.
Key players in the market
Some of the key players in Non-Injectable Insulin market include Generex Biotechnology Corp., Biodel, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Midatech Pharma Plc, Shreya Life Sciences Pvt. Ltd., Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Coromed, Inc., Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Adocia, Oramed Pharmaceuticals, Dance Biopharm, Biocon and Janssen Pharmaceuticals.
Key Developments:
In November 2023, Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio.
In February 2022, Biocon made a significant move by acquiring Viatris' biosimilar portfolio for a substantial sum of USD 3.335 billion. This strategic acquisition bolstered Biocon's biosimilar product offerings and had a positive impact on the company's revenue generation.
Products Covered:
• Oral
• Transdermal
• Nasal
• Sublingual
• Other Products
Dosages Covered:
• Pills
• Sprays
Distribution Channels Covered:
• Hospital Pharmacies
• Online Stores
• Drug Stores
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Non-Injectable Insulin Market, By Product
5.1 Introduction
5.2 Oral
5.3 Transdermal
5.4 Nasal
5.5 Sublingual
5.6 Other Products
6 Global Non-Injectable Insulin Market, By Dosage
6.1 Introduction
6.2 Pills
6.3 Sprays
7 Global Non-Injectable Insulin Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Online Stores
7.4 Drug Stores
8 Global Non-Injectable Insulin Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Generex Biotechnology Corp.
10.2 Biodel, Inc.
10.3 Oramed Pharmaceuticals, Inc.
10.4 Diasome Pharmaceuticals, Inc.
10.5 Midatech Pharma Plc
10.6 Shreya Life Sciences Pvt. Ltd.
10.7 Boston Therapeutics, Inc.
10.8 Diabetology Ltd.
10.9 Emisphere Technologies, Inc.
10.10 Coromed, Inc.
10.11 Novo Nordisk
10.12 Sanofi
10.13 Eli Lilly
10.14 MannKind Corporation
10.15 Adocia
10.16 Oramed Pharmaceuticals
10.17 Dance Biopharm
10.18 Biocon
10.19 Janssen Pharmaceuticals
List of Tables
1 Global Non-Injectable Insulin Market Outlook, By Region (2021-2030) ($MN)
2 Global Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
3 Global Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
4 Global Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
5 Global Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
6 Global Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
7 Global Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
8 Global Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
9 Global Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
10 Global Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
11 Global Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
12 Global Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
13 Global Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
14 Global Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
15 North America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
16 North America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
17 North America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
18 North America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
19 North America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
20 North America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
21 North America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
22 North America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
23 North America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
24 North America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
25 North America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
26 North America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
27 North America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
28 North America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
29 Europe Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
30 Europe Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
31 Europe Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
32 Europe Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
33 Europe Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
34 Europe Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
35 Europe Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
36 Europe Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
37 Europe Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
38 Europe Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
39 Europe Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
40 Europe Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
41 Europe Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
42 Europe Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
43 Asia Pacific Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
44 Asia Pacific Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
45 Asia Pacific Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
46 Asia Pacific Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
47 Asia Pacific Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
48 Asia Pacific Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
49 Asia Pacific Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
50 Asia Pacific Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
51 Asia Pacific Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
52 Asia Pacific Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
53 Asia Pacific Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
54 Asia Pacific Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
55 Asia Pacific Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
56 Asia Pacific Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
57 South America Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
58 South America Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
59 South America Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
60 South America Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
61 South America Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
62 South America Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
63 South America Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
64 South America Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
65 South America Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
66 South America Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
67 South America Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
68 South America Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
69 South America Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
70 South America Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
71 Middle East & Africa Non-Injectable Insulin Market Outlook, By Country (2021-2030) ($MN)
72 Middle East & Africa Non-Injectable Insulin Market Outlook, By Product (2021-2030) ($MN)
73 Middle East & Africa Non-Injectable Insulin Market Outlook, By Oral (2021-2030) ($MN)
74 Middle East & Africa Non-Injectable Insulin Market Outlook, By Transdermal (2021-2030) ($MN)
75 Middle East & Africa Non-Injectable Insulin Market Outlook, By Nasal (2021-2030) ($MN)
76 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sublingual (2021-2030) ($MN)
77 Middle East & Africa Non-Injectable Insulin Market Outlook, By Other Products (2021-2030) ($MN)
78 Middle East & Africa Non-Injectable Insulin Market Outlook, By Dosage (2021-2030) ($MN)
79 Middle East & Africa Non-Injectable Insulin Market Outlook, By Pills (2021-2030) ($MN)
80 Middle East & Africa Non-Injectable Insulin Market Outlook, By Sprays (2021-2030) ($MN)
81 Middle East & Africa Non-Injectable Insulin Market Outlook, By Distribution Channel (2021-2030) ($MN)
82 Middle East & Africa Non-Injectable Insulin Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
83 Middle East & Africa Non-Injectable Insulin Market Outlook, By Online Stores (2021-2030) ($MN)
84 Middle East & Africa Non-Injectable Insulin Market Outlook, By Drug Stores (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
